2022
Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China—The China PEACE Retrospective Heart Failure Study
Yu Y, Guan W, Masoudi FA, Wang B, He G, Spertus JA, Lu Y, Krumholz HM, Li J. Hospital Variation of Spironolactone Use in Patients Hospitalized for Heart Failure in China—The China PEACE Retrospective Heart Failure Study. Journal Of The American Heart Association 2022, 11: e026300. PMID: 36172964, PMCID: PMC9673705, DOI: 10.1161/jaha.122.026300.Peer-Reviewed Original ResearchConceptsSpironolactone prescriptionSpironolactone useHeart failureMedian odds ratioIdeal patientAldosterone antagonistsHospital variationMedian rateReduced ejection fractionUse of spironolactoneMultivariable linear regression modelsHeart Failure StudyEjection fractionHospital characteristicsOdds ratioRepresentative cohortPatientsHospitalChinese hospitalsInappropriate usePrescriptionSpironolactoneSelect individualsAntagonistHigh rate
2020
Geographic Variation in Process and Outcomes of Care for Patients With Acute Myocardial Infarction in China From 2001 to 2015
Zhong Q, Gao Y, Zheng X, Chen J, Masoudi FA, Lu Y, Feng Y, Hu S, Zhang Q, Huang C, Wang Y, Krumholz HM, Li X, Zhou Y. Geographic Variation in Process and Outcomes of Care for Patients With Acute Myocardial Infarction in China From 2001 to 2015. JAMA Network Open 2020, 3: e2021182. PMID: 33095248, PMCID: PMC7584924, DOI: 10.1001/jamanetworkopen.2020.21182.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionProcess of careHospital mortalityMyocardial infarctionOdds ratioAngiotensin receptor blockersCross-sectional studyOutcomes of careReceptor blockersReperfusion therapyPatient characteristicsTherapy useCare measuresPatient hospitalizationIdeal patientOutcome measuresMAIN OUTCOMEΒ-blockersAMI managementPatientsEnzyme inhibitorsSignificant geographic variationMortalityCareHospitalization
2016
Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study
Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L, Group F. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study. European Heart Journal Acute Cardiovascular Care 2016, 6: 232-243. PMID: 26787648, DOI: 10.1177/2048872615626656.Peer-Reviewed Original ResearchConceptsST-segment elevation myocardial infarctionElevation myocardial infarctionFibrinolytic therapyMyocardial infarctionPercutaneous coronary intervention capabilitySequential cross-sectional studiesChina PEACE-Retrospective AMI StudyPrimary reperfusion strategyPercutaneous coronary interventionLittle clinical evidenceCross-sectional studyQuality of careTwo-stage random samplingCoronary interventionHospital delayNeedle timeReperfusion strategySymptom onsetTherapy useClinical evidenceEmergency departmentMedian admissionIdeal patientPatientsWeighted proportion
2015
National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient‐centered Evaluation Assessment of Cardiac Events (PEACE)‐Retrospective AMI Study, 2001, 2006, and 2011
Guan W, Murugiah K, Downing N, Li J, Wang Q, Ross JS, Desai NR, Masoudi FA, Spertus JA, Li X, Krumholz HM, Jiang L, Group T. National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient‐centered Evaluation Assessment of Cardiac Events (PEACE)‐Retrospective AMI Study, 2001, 2006, and 2011. Journal Of The American Heart Association 2015, 4: e001718. PMID: 26071031, PMCID: PMC4599529, DOI: 10.1161/jaha.114.001718.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionHeart failureMyocardial infarctionUse of spironolactoneNational practice patternsProportion of patientsAssessment of eligibilitySpironolactone useAldosterone antagonistsSystolic dysfunctionCardiac eventsAMI patientsChina PatientPatient eligibilityPatient groupUnknown indicationPractice patternsIdeal patientPatientsSpironolactoneEligibilityAppropriate useInfarctionDiabetesNational quality assessmentNational assessment of early β-blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)–Retrospective AMI Study
Zhang H, Masoudi FA, Li J, Wang Q, Li X, Spertus JA, Ross JS, Desai NR, Krumholz HM, Jiang L, Group C. National assessment of early β-blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)–Retrospective AMI Study. American Heart Journal 2015, 170: 506-515.e1. PMID: 26385034, PMCID: PMC5459420, DOI: 10.1016/j.ahj.2015.05.012.Peer-Reviewed Original ResearchConceptsΒ-blocker therapyAcute myocardial infarctionΒ-blocker useCardiogenic shockRisk factorsAbsolute contraindicationMyocardial infarctionEarly β-blocker useLower systolic blood pressureHours of admissionMedical record reviewSystolic blood pressureClinical practice guidelinesLower heart rateQuality of careChest discomfortCardiac eventsBlood pressureRecord reviewChina PatientIdeal patientPractice guidelinesHeart rateHigh riskPatterns of use
2007
Acute Reperfusion Therapy in ST-Elevation Myocardial Infarction from 1994-2003
Nallamothu BK, Blaney ME, Morris SM, Parsons L, Miller DP, Canto JG, Barron HV, Krumholz HM, Investigators R. Acute Reperfusion Therapy in ST-Elevation Myocardial Infarction from 1994-2003. The American Journal Of Medicine 2007, 120: 693.e1-693.e8. PMID: 17679128, PMCID: PMC2020513, DOI: 10.1016/j.amjmed.2007.01.028.Peer-Reviewed Original ResearchConceptsAcute reperfusion therapyST-elevation myocardial infarctionReperfusion therapyMyocardial infarctionIdeal patientPrimary percutaneous coronary interventionPercutaneous coronary interventionNational performance measuresChest painCoronary interventionFibrinolytic therapySymptom onsetNational registryPatientsTherapyInfarctionKey subgroupsAppropriate utilizationTime periodRecent time periodPainRegistryCohortContemporary useImportant opportunity
1997
Determinants of Appropriate Use of Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction in Persons ≥65 Years of Age
Krumholz H, Vaccarino V, Ellerbeck E, Kiefe C, Hennen J, Kresowik T, Gold J, Jencks S, Radford M. Determinants of Appropriate Use of Angiotensin-Converting Enzyme Inhibitors After Acute Myocardial Infarction in Persons ≥65 Years of Age. The American Journal Of Cardiology 1997, 79: 581-586. PMID: 9068512, DOI: 10.1016/s0002-9149(96)00819-3.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAlabamaAngiotensin-Converting Enzyme InhibitorsConnecticutContraindicationsControlled Clinical Trials as TopicDecision MakingDiabetes ComplicationsDiureticsDrug PrescriptionsDrug UtilizationFemaleFollow-Up StudiesHeart FailureHospitalizationHumansIowaMaleMedicaidMultivariate AnalysisMyocardial InfarctionPatient DischargeRetrospective StudiesStroke VolumeTachycardia, VentricularUnited StatesVentricular Function, LeftWisconsinConceptsAcute myocardial infarctionACE inhibitorsMyocardial infarctionDischarge medicationsVentricular functionEnzyme inhibitorsLeft ventricular ejection fractionAngiotensin-converting enzyme inhibitorAngiotensin converting enzyme (ACE) inhibitorsVentricular Enlargement (SAVE) trialCongestive heart failureVentricular ejection fractionYears of ageEligible patientsPatient characteristicsAppropriate patientsDiabetes mellitusEjection fractionHeart failureLoop diureticsMultivariable analysisVentricular tachycardiaIdeal patientObservational studyPatients